Journal profile · ONCOLOGY
Cancer Biomarkers
ISSN 1574-0153 · eISSN 1875-8592 · SAGE Publications (formerly IOS Press) · NETHERLANDS · Bimonthly · Founded 2005
Cancer Biomarkers: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.78; fully open access; APC about USD 3,200; review about 3 months (community reports); community-reported acceptance: about 50%; 62 articles in 2025; indexed in SCIE and Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Cancer Biomarkers is published by SAGE Publications (formerly IOS Press) and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Cancer-related molecular mechanisms research and Circular RNAs in diseases, together about 34.9% of its articles. Its main subfields are Molecular Biology and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. View full journal description This journal is a member of the Committee on Publication Ethics (COPE).
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology13.1%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology11.2%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology10.6%
- Ferroptosis and cancer prognosisMedicine8.8%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.3%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.2%
- Cancer Cells and MetastasisMedicine4.1%
- Inflammatory Biomarkers in Disease PrognosisMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
Early warning / risk: CAS Early Warning Journal List: listed in the 2020 edition (medium risk); not listed in the other 5 editions.LetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.78LetPub ·
- Impact factor (publisher)
- 1.8Publisher website ·
- 5-year impact factor (publisher)
- 2.3Publisher website ·
- CiteScore 2026-06
- 4.3LetPub ·
- SJR 2026-06
- 0.57LetPub ·
- SNIP 2026-06
- 0.56LetPub ·
- h-index
- 33LetPub ·
- h-index
- 68OpenAlex ·
- i10-index
- 1,196OpenAlex ·
- 2-year mean citedness
- 2.73OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 42.32%LetPub ·
Volume
- Articles per year
- 73LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 2,140 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 22 | 22 | 3 |
| 2025 | 62 | 61 | 116 |
| 2024 | 63 | 63 | 282 |
| 2023 | 107 | 107 | 430 |
| 2022 | 131 | 111 | 1,122 |
| 2021 | 146 | 146 | 1,531 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 3,200 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- ≥ 4
- Reference style
- Harvard
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Highlights
- Optional
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted2
- original research articleOriginal Research Article Research Articles should present novel work within the scope of the journal which represents an important advancement in knowledge or …Length not stated
- research articleOriginal Research Article Research Articles should present novel work within the scope of the journal which represents an important advancement in knowledge or …Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Authorship
Please view our authorship policies, which includes information on criteria for authorship, who should be the corresponding author and more. Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
COPE member Model summary
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
Cancer Biomarkers is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, paid by the funder,…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review policy: single anonymized Model summary
The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
Preprint policy: preprints allowed Model summary
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE Publications (formerly IOS Press)
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2005
- ISSN
- 1574-0153
- Electronic ISSN
- 1875-8592
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Biomarkers
What CAS zone is Cancer Biomarkers in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Biomarkers is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Biomarkers?
The latest impact factor listed by LetPub is 1.78; CiteScore 4.3, h-index 68.
How long does peer review take at Cancer Biomarkers?
Authors report an average review time of about 3 months; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Biomarkers?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: ≥ 4; Reference style: Harvard; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Highlights: Optional; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Cancer Biomarkers?
According to LetPub and DOAJ records, Cancer Biomarkers is indexed in SCIE and Scopus.
Is Cancer Biomarkers open access, and what is the APC?
Cancer Biomarkers is a fully open-access journal. APC about USD 3,200.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .